NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Alamar Biosciences ALMR

Alamar Biosciences listed on Nasdaq on 17 Apr 2026 and is not in the S&P 500. It is worth $2.0 billion. Its price history starts on 17 Apr 2026. 7 directors have filed with the SEC in the last 12 months (who counts), 2 of them executives. 3 other officers are on file. At 30 Jun 2026, Sands Capital Alternatives was its largest institutional holder, with 6.1% of the company.

CEO
Yuling Luo
Listed
17 Apr 2026 on Nasdaq, IPO filings and terms
Headquarters
Fremont, CA
Market cap
$2.0B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2026, from Alamar Biosciences's quarterly filings.

Quarters since Mar 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Mar 2025 to Sep 2026

$0$10M$20M$30M$40M20252026$34M

Revenue breakdown

Alamar Biosciences's $34M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.

Quarter to Sep 2026

  • Consumables$18M, 53.2%
  • Instruments$8M, 25.2%
  • Service$7M, 21.6%

Alamar Biosciences's market cap since April 2026

Weekly, up to 13 Nov 2026

May 2026JunJulAugSepOctNov$2.1B

Board and leadership

Board and officers

1 person here also holds roles at other S&P 500 companies.

Roles filed up to 30 Sep 2026

NameTitle
Directors (7)
Yuling LuoChief Executive OfficerChief Executive Officer
Rebecca ChambersDirectorDirector
Shiping ChenChief Operating OfficerChief Operating Officer
Nicholas NaclerioDirectorDirector
Robert P. RagusaDirectorDirector
Ian W. RatcliffeDirectorDirector
Frank WitneyDirectorAlso at RevvityDirector
Officers (3)
Justin J. McAnearChief Financial OfficerLast filed 20 Apr 2026Chief Financial Officer
John L. BrottemGeneral CounselLast filed 16 Sep 2026General Counsel
Timothy Ogden WhitePresidentLast filed 20 Apr 2026President

Owners and trading

Largest institutional holders

Each fund group's share of Alamar Biosciences. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Sands Capital Alternatives6.1%
  • Samsara Biocapital3.6%
  • T. Rowe Price3.2%
  • Ark Investment Management2.0%
  • Braidwell1.6%

These five hold 16.4% of Alamar Biosciences.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $4.0 million in 1 purchase in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
20 Apr 2026BuyNicholas NaclerioDirectorDirectorBuy235,294$4.0M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 departure and 1 appointment of directors and officers in the last two years.

Left the company or board 1Appointed 1WARN layoff notices 0Large insider sales 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.